Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
HEXIMA LIMITED |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.018 AUD | 0.00% | 0.00% | -10.00% | |
| Nov. 29 | Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director | CI |
| Sep. 19 | Hexima Limited Appoints Phillip Hains as A Non-Executive Director | CI |
| Sales 2023 | 1.48M 982K | Sales 2024 * | - | Capitalization | 3.51M 2.32M |
|---|---|---|---|---|---|
| Net income 2023 | -1M -661K | Net income 2024 * | - | EV / Sales 2023 | 0,89x |
| Net cash position 2023 | 2.19M 1.45M | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
| P/E ratio 2023 | -1,83x | P/E ratio 2024 * | Employees | - | |
| Yield 2023 | - | Yield 2024 * |
-
| Free-Float | 36.17% |
More Fundamentals
* Assessed data
More news
| Current month | -21.74% | ||
| 3 months | -18.18% | ||
| 6 months | +20.00% | ||
| Current year | -10.00% |
1 week
0.02
0.02
1 month
0.020.02
Current year
0.010.02
1 year
0.010.02
3 years
0.010.50
5 years
0.010.50
10 years
0.010.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2014 | |
Leanne Ralph
SEC | Corporate Secretary | - | 2021 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2014 | |
Zhen Nan Yap
BRD | Director/Board Member | - | 2018 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-07 | 0.018 | 0.00% | 56 000 |
| 23-12-06 | 0.018 | 0.00% | 79,635 |
| 23-12-05 | 0.018 | 0.00% | 20,000 |
Delayed Quote Australian Stock Exchange, December 07, 2023 at 07:40 pm EST
More quotes
Hexima Limited is an Australia-based clinical-stage, anti-infectives focused biotechnology company. The Company is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The Company is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. It is also investigating the application of its plant defensin technology to other human fungal diseases.
Calendar
2024-02-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.00% | 2 M $ | |
| +69.89% | 41 191 M $ | |
| +4.93% | 39 236 M $ | |
| -55.49% | 30 484 M $ | |
| -27.50% | 27 837 M $ | |
| +38.06% | 22 079 M $ | |
| -25.41% | 22 245 M $ | |
| -1.81% | 16 633 M $ | |
| -12.95% | 11 376 M $ | |
| -17.93% | 10 762 M $ |
